The Madras High Court's analysis of evidence under Section 107A for regulatory approval highlights the complexities involved with the Bolar exemption. While clarity is provided, the ruling poses challenges for manufacturers that could hinder the provision's intended purpose.
Novartis v. Venkata Narayana Active Ingredients: Bolar Exemption Explored
The Madras High Court’s ruling in Novartis AG v. Venkata Narayana Active Ingredients provides critical insights into the evidentiary requirements under Section 107A of the Patents Act, which addresses exemptions for obtaining regulatory approvals through export.
The Court's examination aims to clarify the necessary evidence needed to invoke the Bolar exemption but raises substantial concerns regarding the practical burdens imposed on manufacturers. The potential for excessive evidentiary requirements may inadvertently undermine the essence of the Bolar exemption, thereby complicating the legislative intent to facilitate quicker availability of generic drugs.
By parsing the evidentiary standards, the Court attempts to provide regulatory clarity, yet the risks associated with undermining manufacturers’ ability to meet the criteria set forth could stifle innovation within the pharmaceutical sector.
For legal practitioners involved in the pharmaceutical and patents space, this ruling necessitates careful consideration of the evidentiary landscape when navigating regulatory approvals and defenses based on the Bolar exemption in future cases.
Citations
- Novartis AG v. Venkata Narayana Active Ingredients (2026) 4 ILR 511
